Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association Between Sglt2 (Sodium-Glucose Cotransporter-2) Inhibitors and Bladder Cancer in Individuals With Type 2 Diabetes; a Systematic Review and Meta-Analysis Publisher



Mohammadtabar M1 ; Fazeli A2 ; Parsai N3 ; Aboulfathiyarmohammadyar Z4 ; Shafiei E5 ; Khaledi M3 ; Zaremoghadam E6 ; Sisakht AR7 ; Mohammadi S8 ; Mardanparvar H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Ophthalmology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Education, Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  4. 4. Student Committee Research, School of Pharmacy (Pharm D), Eastern Mediterranean University of North Cyprus, Famagusta, Cyprus
  5. 5. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
  7. 7. Student Research Committee, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  8. 8. Student Research Committee, School of Dentistry, European University of Georgia, Tibilisi, Georgia

Source: Journal of Nephropathology Published:2023


Abstract

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant. Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively. Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014). © 2023 The Author(s);.
Related Docs
View other Related Docs
1. Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2i); As a Preventive Factor of Kidney Failure in Patients With Type 2 Diabetes; a Meta-Analysis of Randomized Controlled Trials, Journal of Renal Injury Prevention (2021)
2. Antianginal Effects of Empagliflozin in Patients With Type 2 Diabetes And Refractory Angina; a Randomized, Double-Blind Placebo-Controlled Trial (Empt-Angina Trial), Clinical Cardiology (2024)
3. Investigating the Association Between the Administration of Sglt-2 Inhibitors and the Risk of Urinary Tract Infection; a Systematic Review and Meta-Analysis, Journal of Renal Injury Prevention (2024)
4. Dapagliflozin in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis on Randomized, Double-Blind, Placebo-Controlled Multicenter Trials, Journal of Nephropathology (2025)
5. Administration of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Patients With Diabetes: A Systematic Review and Meta-Analysis, Journal of Nephropathology (2023)
6. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Insulin Resistance; a Systematic Review and Meta-Analysis, Acta Diabetologica (2023)
7. Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Anthropometric Indices and Metabolic Markers in Overweight/Obese Individuals Without Diabetes: A Systematic Review and Meta-Analysis, Current Medical Research and Opinion (2022)
8. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)], Innovative Medicine of Kuban (2024)
Experts (# of related papers)
View all Related Experts
Nizal Sarrafzadegan (3)
Davood Shafie (1)
Other Related Docs
9. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 2)], Innovative Medicine of Kuban (2025)
10. Metformin Protects Renal Tubular Cells; Mechanisms and New Concepts, Journal of Nephropathology (2018)
11. The Effect of Nettle (Urtica Dioica) Supplementation on the Glycemic Control of Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis, Phytotherapy Research (2020)